Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 114Recruiting 101Terminated 44Unknown 36Not yet recruiting 22Active not recruiting 20Withdrawn 17Suspended 4Enrolling by invitation 2

Sponsor Class

OTHER 4NIH 2INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Immunoblastic Lymphadenopathy 1GATA2 Deficiency 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 10Cisplatin 7Bevacizumab 7pembrolizumab 6Radiosurgery 6Oxaliplatin 5Nivolumab 5Irinotecan 5Fluorouracil 5Everolimus 5Capecitabine 5Biopsy 5venetoclax 4fludarabine 4S 1 (combination) 4Prednisone 4Leucovorin 4Gemcitabine 4Etoposide 4Drug Therapy 4Doxorubicin 4Azacitidine 4fludarabine phosphate 3Vincristine 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × OTHER × Azacitidine × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05955261 2026-04-23

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

St. Jude Children's Research Hospital

Phase 2 Suspended
70 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06158100 2025-08-06

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

University of Miami

Phase 1 Suspended
25 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡